Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q35011925

about

The emerging role of FTY720 (Fingolimod) in cancer treatment FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.Toward a Cancer Drug of Fungal Origin Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Novel targeted therapies for mantle cell lymphoma A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma.Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.Protein phosphatase 2A: a target for anticancer therapy.The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015).Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics.A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53.OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro.A genome-wide screen for FTY720-sensitive mutants reveals genes required for ROS homeostasis.Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives.Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.Therapeutic Targeting of PP2A.Lysophosphatidic acid aberrancies and hepatocellular carcinoma: studies in the MDR2 gene knockout mouse.More than Just an Immunosuppressant: The Emerging Role of FTY720 as a Novel Inducer of ROS and Apoptosis.Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma

P2860

Q26748927-86275204-70D3-41F1-85FE-5AD95E8B1866 Q29248124-20839E87-F7BB-4C93-957A-DAFB943CA17B Q30535265-D5BD23E2-8B14-42D0-AB75-4EADD01EAF8D Q34266856-3122D69A-C309-4D43-AA06-D90D3284F6CF Q34747359-FF9FF361-E5BF-4C3D-AC44-0C7DA5F85807 Q35596957-9EB24E83-7416-406C-9214-1F334E43AE3C Q35845241-2DC7E1EA-7B28-4DB4-A7F3-8538132303C6 Q35889841-3BFF6466-0FF5-4900-8737-52A06ABB2957 Q35953902-B508FCB8-4B6C-441C-B779-6AE05BFCEECB Q37109693-CF06E82C-C5BA-4E16-945B-1136E772E0F6 Q37169105-41638708-0F73-4FB8-B2B1-CBDDCFCD4A19 Q37200863-0F8B4E83-ADEC-4E41-BE06-FFA00945D0B0 Q37675273-874E91AE-5BA4-4E79-ACF3-CE970E8B1689 Q38103646-E8EF7BDA-6314-4828-9048-294143948993 Q38546700-8C82C8BC-168C-4626-B748-50ED619F96AD Q38725557-0E435D2A-727C-4C3F-A1B3-369A8C9B106D Q38904928-09214062-92FC-41EC-AF29-273DB78C2DC1 Q38943724-C289A332-FF69-4B7E-8AD6-05E55DD83F49 Q38945994-EC14E9D3-F030-479D-B800-4B1DAABBBD65 Q39106527-F925EF85-AE5C-422A-9ABE-D9E21F4F191F Q39354121-DBAFDB6A-E415-4734-BB7E-1BAC92E1D637 Q40859498-54D2B8AB-69FD-4A9E-9A23-D43BA45A5A65 Q42362014-AC12DDB5-CFFB-4037-9B6A-D22C88EC9559 Q43170996-68C6495E-9930-4273-A72E-7D88B5D53DF0 Q46242463-81216D94-4BFA-4C5A-8E8D-0CDD67074676 Q46480750-744A1E33-76CD-43FD-9CAD-19A6F869FFAE Q46554788-24C6D6FE-398C-4B5D-B631-D0CECEE8EC45 Q47436859-6C2A8431-DD82-4FF4-B7E1-90C4625FF526 Q53258855-C465D5BA-2732-4BD5-ABAE-3C74C7D94C7E Q55281738-62F2808A-6F9E-4AFB-BCE5-1A18777EA3CA Q58701446-F104DC6F-0918-47EF-863C-C716D6853228

P2860

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q35011925

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@ast

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@en

type

label

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@ast

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@en

prefLabel

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@ast

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@en

P1433

Q35011925-67A9BA85-96FB-481E-872C-031C85B5C380

P1476

Q35011925-F302490D-A4E3-4B49-8289-E3296EB4378E

P2093

Q35011925-0A520F5A-0895-4D0E-9BEE-129333AE1E47

Q35011925-0BCA47FB-4717-4DD8-91EA-1E2E54F8753B

Q35011925-4C31CB1F-88B7-41F1-832C-403669857888

Q35011925-6741D638-D9B9-447B-AEAF-A346B703EB8B

Q35011925-6F71FDB7-F684-42F7-8790-BB09A74DA33E

Q35011925-79ED7562-3CE4-433E-87C5-D74203F616DC

Q35011925-7E67CA40-3596-4D1F-B4F3-A6FD62792724

Q35011925-8DFC32D1-4D77-4D7A-A297-559DA6F94232

Q35011925-8E68A9D6-1A6A-488B-8BF9-19F9A425FC85

Q35011925-B2A18E65-0068-48A6-89ED-D08282DDF6FC

P2860

Q35011925-10CA4473-D832-4335-99BF-8A0B6360DF4A

Q35011925-278870E2-13BA-4773-A3D0-734E311351BC

Q35011925-2CAEDA74-F0F7-4225-B186-3165D8D43769

Q35011925-430A2643-E2E1-40AE-A174-090DF7FD82DC

Q35011925-43B7C8D0-EA03-4E9A-9248-9BA822183D6C

Q35011925-468F9AFB-F157-44EA-BD18-EB9FDD4AD4F4

Q35011925-4709F880-42FA-4410-88BD-3555B0993FED

Q35011925-4D51C7A2-8308-4373-B66A-B89E9529E9EC

Q35011925-4DCB0464-8C07-496D-9381-236CFCF6278A

Q35011925-5069C971-B4BC-4CE6-A88C-8C8BCABD5A08

P304

Q35011925-23D733DE-FDAC-4AFC-9A21-33FAF22D95C3

P31

Q35011925-20030C1F-EABD-4CF6-B734-602336B3F727

P356

Q35011925-9DEEDC5D-DE79-46AD-9576-5F4CCC451D6E

P407

Q35011925-444347E8-1B7B-47C1-86A5-222EA7FE7D54

P433

Q35011925-59BCA8F8-5CCC-41DD-8F64-45185A9935D6

P478

Q35011925-425E7B8D-D2E9-4CB0-A220-E2702D94A7E0

P50

Q35011925-E96BDF08-643C-4725-B50F-D4FECE9FD413

P577

Q35011925-4013FFC5-4140-47CE-BEE6-E8C606B053B2

P5875

Q35011925-343F40E6-87D0-4E5E-9246-E15EE01A5AF3

P698

Q35011925-BF95A45B-36D9-496B-A224-0A71CD627BB1

P932

Q35011925-99235843-EE4F-471D-874A-CA6C5FDE2D62

P356

P1433

P1476

Antitumor effects of OSU-2S, a ...... , in hepatocellular carcinoma.

@en

P2093

Chih-Chien Chou

http://www.w3.org/2001/XMLSchema#string

Ching-Shih Chen

http://www.w3.org/2001/XMLSchema#string

Dasheng Wang

http://www.w3.org/2001/XMLSchema#string

Hany A Omar

http://www.w3.org/2001/XMLSchema#string

Jui-Hsiang Hung

http://www.w3.org/2001/XMLSchema#string

Lisa D Berman-Booty

http://www.w3.org/2001/XMLSchema#string

Luigi Terracciano

http://www.w3.org/2001/XMLSchema#string

Natarajan Muthusamy

http://www.w3.org/2001/XMLSchema#string

Samuel K Kulp

http://www.w3.org/2001/XMLSchema#string

Takayuki Kogure

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

NOX enzymes and the biology of reactive oxygen

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers

FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.

Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells.

Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.

"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.

The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival.

Opportunities for targeted therapies in hepatocellular carcinoma.

P304

1943-1958

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.24293

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50353192

http://www.w3.org/2001/XMLSchema#string

P698

21391227

http://www.w3.org/2001/XMLSchema#string

P932

3103615

http://www.w3.org/2001/XMLSchema#string